OBJECTIVES: Upon completion of this activity, the participant should be able to:  (1) Discuss the patient's case and treatment in view of the NCCN Guidelines and the molecular findings, (2) Enumerate how the molecular findings and the literature around these findings may affect the treatment of the patient, (3) Generate an appropriate treatment plan based on the science and literature discussed in the tumor board, (4). Communicate the discussion and its results to the treating team for each patient.

PLANNER/MODERATOR DISCLOSURE: Robert Mennel, MD, has no relevant financial relationship(s) to disclose with companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.  Michelle Shiller, MD, is/was a speaker/advise board for Astra Zeneca, Merck, Genentech, Mirati, Amgen, Takeda, and BMS Companies.

All relevant financial relationships have been mitigated.

ACCREDITATION: The A. Webb Roberts Center for Continuing Medical Education of Baylor Scott & White Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

DESIGNATION:  The A. Webb Roberts Center for Continuing Medical Education of Baylor Scott & White Health designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABS CC: Successful completion of this CME activity enables the learner to earn credit toward the CME requirement of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit.

For information, please contact Lidya Gebresellassie at Lidya.Gebresellassie@bswhealth.org